Science
A full FDA approval, phase 3 visceral-fat data, and lessons for evaluating its gray-market cousins.
Tesamorelin is the rare GH-axis peptide with a complete regulatory dossier: GMP manufacturing, phase 3 trials, and an FDA approval for HIV-associated lipodystrophy. That makes it a useful benchmark for what proven GHRH-analog pharmacology looks like.
The comparison illuminates its unapproved cousins: CJC-1295 shares the mechanism class but not the evidence, and the gap between the two is a case study in why approval status belongs in every compound evaluation.
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchAngiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.
ScienceSURMOUNT-5 and real-world cohorts consistently favor the dual agonist on weight endpoints — with nuances the headlines skip.
ResearchThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
